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5eft Ventricular Mass and
he Outcome of Patients With
ypertrophic Cardiomyopathy
read with great interest the study by Olivotto et al. (1), which
oncluded that the left ventricular (LV) mass by cardiovascular
agnetic resonance proved more sensitive than a maximal LV
hickness 30 mm in predicting outcome of patients with hypertro-
hic cardiomyopathy. However, as stated in an Editorial Comment by
eichek (2), the number of cardiac deaths in the study was small. In
ther words, LV mass by cardiovascular magnetic resonance did not
rove more sensitive in predicting outcome in the presently enrolled
atients. What happened when the authors chose other end points
uch as progression to severe functional limitation (New York Heart
ssociation functional class III or IV) and/or sustained, life-
hreatening ventricular arrhythmias requiring the implantation of a
ardioverter-defibrillator that are used for the entire cohort of patients
ith hypertrophic cardiomyopathy as previously described (3)? If the
forementioned end points were chosen, did LV mass prove more
ensitive than a maximal LV thickness 30 mm in predicting the
utcome of patients with hypertrophic cardiomyopathy? In addition,
hat were the causes of death in the study by Olivotto et al. (1)?
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lease note: The author would like to thank the Editors of JACC for the opportunity
o ask these questions about such an important article.
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eply
e are grateful to Dr. Song for his interest in our work (1). He
oses questions regarding the choice of the end point for our studynd the definition of the causes of death. With regard with the first
uestion, Dr. Song is correct in pointing out that the only end
oint assessed in our study was cardiovascular mortality. This
hoice was unavoidable, given the relatively short duration of
ollow-up available, consequent to the recent introduction of
ardiovascular magnetic resonance to clinical cardiology and hy-
ertrophic cardiomyopathy (HCM). Symptom progression to
ew York Heart Association functional class III to IV is a slowly
volving process in HCM and can be meaningfully assessed only
ver the course of several years or even decades. For example, our
ther study cited by Dr. Song (2), in which a combined end point
as in fact employed, had a mean follow-up of 12 years, compared
ith 2.6 years in the present study (1).
With regard to the definition of causes of death and with all due
espect, we believe that we have provided the relevant information
n the Results section of the report (1). Over a 2.6-  0.7-year
ollow-up, there were 10 HCM-related events: 5 sudden death
vents (including 1 resuscitated cardiac arrest and 2 appropriate
mplanted cardioverter-defibrillator discharges for life-threatening,
ustained ventricular arrhythmias), 3 deaths due to progressive heart
ailure, and 2 after surgical septal myectomy. The causes of death in
ur HCM patients were classified according to standard definitions
hat we have consistently employed in prior studies (2–5).
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